201 related articles for article (PubMed ID: 20153443)
1. The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes.
Peng S; Lacerda AE; Kirsch GE; Brown AM; Bruening-Wright A
J Pharmacol Toxicol Methods; 2010; 61(3):277-86. PubMed ID: 20153443
[TBL] [Abstract][Full Text] [Related]
2. Quantified proarrhythmic potential of selected human embryonic stem cell-derived cardiomyocytes.
Jonsson MK; Duker G; Tropp C; Andersson B; Sartipy P; Vos MA; van Veen TA
Stem Cell Res; 2010 May; 4(3):189-200. PubMed ID: 20303332
[TBL] [Abstract][Full Text] [Related]
3. Human stem cell-derived cardiomyocytes detect drug-mediated changes in action potentials and ion currents.
Gibson JK; Yue Y; Bronson J; Palmer C; Numann R
J Pharmacol Toxicol Methods; 2014; 70(3):255-67. PubMed ID: 25219538
[TBL] [Abstract][Full Text] [Related]
4. Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG.
Jonsson MK; Vos MA; Mirams GR; Duker G; Sartipy P; de Boer TP; van Veen TA
J Mol Cell Cardiol; 2012 May; 52(5):998-1008. PubMed ID: 22353256
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Possible Proarrhythmic Potency: Comparison of the Effect of Dofetilide, Cisapride, Sotalol, Terfenadine, and Verapamil on hERG and Native IKr Currents and on Cardiac Action Potential.
Orvos P; Kohajda Z; Szlovák J; Gazdag P; Árpádffy-Lovas T; Tóth D; Geramipour A; Tálosi L; Jost N; Varró A; Virág L
Toxicol Sci; 2019 Apr; 168(2):365-380. PubMed ID: 30561737
[TBL] [Abstract][Full Text] [Related]
6. In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes.
Caspi O; Itzhaki I; Kehat I; Gepstein A; Arbel G; Huber I; Satin J; Gepstein L
Stem Cells Dev; 2009; 18(1):161-72. PubMed ID: 18510453
[TBL] [Abstract][Full Text] [Related]
7. Human embryonic stem cell derived cardiac myocytes detect hERG-mediated repolarization effects, but not Nav1.5 induced depolarization delay.
Qu Y; Gao B; Fang M; Vargas HM
J Pharmacol Toxicol Methods; 2013; 68(1):74-81. PubMed ID: 23518063
[TBL] [Abstract][Full Text] [Related]
8. Action potential experiments complete hERG assay and QT-interval measurements in cardiac preclinical studies.
Ducroq J; Printemps R; Guilbot S; Gardette J; Salvetat C; Le Grand M
J Pharmacol Toxicol Methods; 2007; 56(2):159-70. PubMed ID: 17604185
[TBL] [Abstract][Full Text] [Related]
9. Safety pharmacology assessment of drug-induced QT-prolongation in dogs with reduced repolarization reserve.
Vormberge T; Hoffmann M; Himmel H
J Pharmacol Toxicol Methods; 2006; 54(2):130-40. PubMed ID: 16757186
[TBL] [Abstract][Full Text] [Related]
10. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
Bottino D; Penland RC; stamps A; Traebert M; Dumotier B; Georgiva A; Helmlinger G; Lett GS
Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428
[TBL] [Abstract][Full Text] [Related]
11. Human embryonic stem cell-derived cardiomyocytes: demonstration of a portion of cardiac cells with fairly mature electrical phenotype.
Pekkanen-Mattila M; Chapman H; Kerkelä E; Suuronen R; Skottman H; Koivisto AP; Aalto-Setälä K
Exp Biol Med (Maywood); 2010 Apr; 235(4):522-30. PubMed ID: 20407085
[TBL] [Abstract][Full Text] [Related]
12. Validation of a voltage-sensitive dye (di-4-ANEPPS)-based method for assessing drug-induced delayed repolarisation in beagle dog left ventricular midmyocardial myocytes.
Hardy ME; Pollard CE; Small BG; Bridgland-Taylor M; Woods AJ; Valentin JP; Abi-Gerges N
J Pharmacol Toxicol Methods; 2009; 60(1):94-106. PubMed ID: 19414070
[TBL] [Abstract][Full Text] [Related]
13. Additive effects of ziprasidone and D,L-sotalol on the action potential in rabbit Purkinje fibres and on the hERG potassium current.
Ducroq J; Printemps R; Le Grand M
J Pharmacol Toxicol Methods; 2005; 52(1):115-22. PubMed ID: 15922632
[TBL] [Abstract][Full Text] [Related]
14. A step towards characterisation of electrophysiological profile of torsadogenic drugs.
Champeroux P; Ouillé A; Martel E; Fowler JS; Maurin A; Richard S; Le Guennec JY
J Pharmacol Toxicol Methods; 2011; 63(3):269-78. PubMed ID: 21224008
[TBL] [Abstract][Full Text] [Related]
15. The comparative sensitivity of three in vitro safety pharmacology models for the detection of lidocaine-induced cardiac effects.
Goineau S; Castagné V; Guillaume P; Froget G
J Pharmacol Toxicol Methods; 2012 Jul; 66(1):52-8. PubMed ID: 22691624
[TBL] [Abstract][Full Text] [Related]
16. A novel method of selecting human embryonic stem cell-derived cardiomyocyte clusters for assessment of potential to influence QT interval.
Yamazaki K; Hihara T; Taniguchi T; Kohmura N; Yoshinaga T; Ito M; Sawada K
Toxicol In Vitro; 2012 Mar; 26(2):335-42. PubMed ID: 22198052
[TBL] [Abstract][Full Text] [Related]
17. Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays.
Harris K; Aylott M; Cui Y; Louttit JB; McMahon NC; Sridhar A
Toxicol Sci; 2013 Aug; 134(2):412-26. PubMed ID: 23690542
[TBL] [Abstract][Full Text] [Related]
18. Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds.
Himmel HM
J Pharmacol Toxicol Methods; 2013; 68(1):97-111. PubMed ID: 23702537
[TBL] [Abstract][Full Text] [Related]
19. Selective block of IKs plays a significant role in MAP triangulation induced by IKr block in isolated rabbit heart.
Guérard NC; Traebert M; Suter W; Dumotier BM
J Pharmacol Toxicol Methods; 2008; 58(1):32-40. PubMed ID: 18582585
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Batch Variations in Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes from 2 Major Suppliers.
Huo J; Kamalakar A; Yang X; Word B; Stockbridge N; Lyn-Cook B; Pang L
Toxicol Sci; 2017 Mar; 156(1):25-38. PubMed ID: 28031415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
